BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Real-time BOERSE MUENCHEN 03:45:58 2024-07-16 pm EDT | ||
| 1,272 EUR | -0.51% |
|
| Current month | +3.61% | ||
| 1 month | +10.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 1,272 | -0.51% |
| 24-07-15 | 1,278 | -0.43% |
| 24-07-12 | 1,284 | +2.14% |
| 24-07-11 | 1,257 | -0.88% |
| 24-07-10 | 1,268 | +0.50% |
Real-time BOERSE MUENCHEN
Last update July 16, 2024 at 03:45 pm EDT
More quotesStatic data
| Product type | Certificati Bonus e Protezione parz. |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD6AXH |
| ISIN | DE000HD6AXH1 |
| Date issued | 2024-06-14 |
| Strike | 1,300 $ |
| Maturity | 2024-09-20 (66 Days) |
| Parity | 1 : 1 |
| Emission price | 1,144 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,284 € |
|---|---|
| Lowest since issue | 1,134 € |
| Spread | 0.95 € |
| Spread % | 0.07% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
893.8
USD
Spread / Average Target
-5.08%
- Stock Market
- Certificates
- Certificat
